The Neuron-Specific Enolase Assessment in Patients with Neuroendocrine Tumors with or without Carcinoid Syndrome Abstract #1197

Introduction: NeuroEndocrine Tumors (NETs) comprises a wide area of clinical presentations and neuroendocrine markers.
Aim(s): We focused on Neuron-Specific Enolase (NSE) assay in NETs.
Materials and methods: This is an observational study in patients with NETs, with at least 1 endocrine evaluation at C.I.Parhon National Institute of Endocrinology, Bucharest, between 2008-2014. Clinical evaluation (including the confirmation of carcinoid syndrome), neuroendocrine markers were assessed: chromogranin A (normal < 100ng/mL), serotonin (normal < 240 ng/mL), and serum NSE (normal <12ng/mL).
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD Mara Carsote

To read results and conclusion, please login ...

Further abstracts you may be interested in

#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#341 Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kjell Oberg
Authors: Oberg K, Anthony L, Sideris L, Chen L T, ...
#736 The Bone Metastasis Phenotype in Patients Diagnosed with Neuroendocrine Tumors
Introduction: Bone metastasis (BM) is actively searched especially in patients (p) with a long history of NET.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Catalina Poiana
Authors: Carsote M, Ene C, Popescu M, Petris R, ...
#915 Thyroid Disturbances in Neuroendocrine Tumors: A Romanian Retrospective Study
Introduction: For the last decades, neuroendocrine tumors (NETs) was a large area of investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Mara Carsote
#559 The Bone Scintigram in Patients with Neuroendocrine Tumors - A Series of 12 Cases
Introduction: The bone metastasis finding is based on imaging or aggressive features as high Ki-67 or rapidly progressive disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mara Carsote
Keywords: neuroendocrine, bone
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.